Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $3.50, but opened at $3.85. Raia Drogasil shares last traded at $3.85, with a volume of 1,075 shares changing hands.
Raia Drogasil Price Performance
The business has a 50-day simple moving average of $3.57 and a two-hundred day simple moving average of $4.19.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $2.17 billion for the quarter, compared to the consensus estimate of $2.32 billion. On average, equities research analysts anticipate that Raia Drogasil S.A. will post 0.17 EPS for the current fiscal year.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
